STOCK TITAN
  1. Home
  2. News
  3. BIVI

BioVie Inc - BIVI STOCK NEWS

Welcome to our dedicated news page for BioVie (Ticker: BIVI), a resource for investors and traders seeking the latest updates and insights on BioVie.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect BioVie's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of BioVie's position in the market.

News
Genetic Technologies and BioVie Interviews to Air on the RedChip Small Stocks Big Money(R) Show on Bloomberg TV
Rhea-AI Summary
RedChip Companies will air interviews with Genetic Technologies Limited (NASDAQ:GENE) and BioVie, Inc. (NASDAQ:BIVI) on The RedChip Small Stocks Big Money® Show, a sponsored program on Bloomberg TV, this Saturday, December 30, at 7 p.m. Eastern Time (ET). Genetic Technologies is executing a B2B commercialization strategy for its flagship geneType multi-risk test covering various diseases, with a global market expected to reach $4.6 billion by 2025. BioVie is a clinical-stage company developing transformative therapies for Alzheimer's, Parkinson's, and liver diseases, with positive trending data from a Phase 3 trial in AD.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.7%
Tags
none
-
News
Rail Vision and BioVie Interviews to Air on the RedChip Small Stocks Big Money(R) Show on Bloomberg TV
Rhea-AI Summary
RedChip Companies will air interviews with Rail Vision (NASDAQ:RVSN) and BioVie, Inc. (NASDAQ:BIVI) on The RedChip Small Stocks Big Money® Show on Bloomberg TV this Saturday, December 23, at 7 p.m. Eastern Time (ET). Rail Vision is a company at the forefront of an evolution in train safety, providing AI-based detection systems for obstacle identification on and near tracks. Knorr Bremse, a key strategic investor, has invested $25M across two investment cycles. BioVie is a clinical-stage company developing transformative therapies for neurodegeneration and liver disease, with positive trending data from a Phase 3 trial in Alzheimer's and Parkinson's. The company plans to launch Phase 3 trials in 2024 and has multiple other efforts underway that may create additional catalysts.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.81%
Tags
none
-
News
BioVie Announces Efficacy Data from Phase 3 Trial of NE3107 in Patients with Mild to Moderate Alzheimer’s Disease
Rhea-AI Summary
BioVie Inc. (NASDAQ: BIVI) announced positive analysis of unblinded, topline efficacy data from its Phase 3 clinical trial of NE3107 in the treatment of mild to moderate Alzheimer’s Disease. The trial showed NE3107’s treatment advantage over placebo to potentially be equal to or greater than data reported from clinical trials for the approved medications for AD without the associated safety concerns. The trial started during the COVID-19 pandemic, enrolling 439 patients through 39 sites. The trial identified significant deviations from protocol and Good Clinical Practice (GCP) violations at 15 sites, leading to exclusions and referral to the U.S. Food and Drug Administration (FDA) Office of Scientific Investigations (OSI) for further action. After exclusions, 81 patients remained in the Modified Intent to Treat (MITT) population, 57 of whom were in the Per-Protocol population.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-60.72%
Tags
clinical trial
News
BioVie Presents Positive Clinical Safety Data from Phase 2b Trial of BIV201 in Refractory Ascites at the American Association for the Study of Liver Disease (AASLD) - The Liver Meeting® 2023
Rhea-AI Summary
BioVie Inc. (NASDAQ: BIVI) announces positive clinical safety data from Phase 2b study of BIV201, a continuous infusion of terlipressin, in combination with standard of care for patients with refractory ascites due to cirrhosis. The data supports the acceleration of BIV201 into Phase 3 trials, with a commitment to commence in Q2 2024. The results show favorable safety profile and well-tolerated combination with standard of care, encouraging further development and investigation in confirmatory trials.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.57%
Tags
clinical trial
-
News
BioVie to Participate in the Truist Securities BioPharma Symposium
Rhea-AI Summary
BioVie Inc. announced the participation of its management team in the Truist Securities BioPharma Symposium to be held in New York on November 8-9, 2023. The symposium will include a panel presentation on 'Exploring Late-Stage New Modalities in Alzheimer's Disease' and one-on-one investor meetings. For more information, contact Truist Securities.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.61%
Tags
conferences
-
News
BioVie to Host Conference Call and Webcast Wednesday November 1, 2023 at 8:00 AM ET
Rhea-AI Summary
BioVie Inc. announced that its management will host a conference call and webcast on November 1, 2023, to review recent data on NE3017 presented at the CTAD conference. The call will be led by BioVie's President and CEO Cuong Do, Chief Medical Officer Dr. Joseph Palumbo, and Dr. Steven Arnold of Harvard Medical School.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
21.32%
Tags
conferences
News
BioVie Announces Late-Breaking Abstract Presenting Clinical Safety Data from the Company’s Ascites Phase 2 Trial Accepted for Presentation at AASLD – The Liver Meeting® 2023
Rhea-AI Summary
BioVie to present clinical safety data on BIV201 at AASLD conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.54%
Tags
clinical trial
-
News
Blinded Data Presented at CTAD Suggest that NE3107 is Biologically Active and May Have Impact on Cognitive, Biomarker, and Imaging Endpoints Among Mild to Moderate Alzheimer’s Disease Patients
Rhea-AI Summary
BioVie presents blinded data on cognitive, biomarker, and imaging findings from Phase 3 trial of NE3107 in Alzheimer's Disease at CTAD. Statistically significant population changes observed in cognitive and functional assessments. Reduction in amyloid burden observed. Increases in insulin and beta cell function without hypoglycemia. Increased FDG-PET SUVRs suggestive of reduced amyloid burden. Unblinded, topline data expected in late November or early December.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.97%
Tags
none
-
News
BioVie to Present Blinded Data on NE3107 in the Treatment of Mild to Moderate Alzheimer’s Disease at CTAD
Rhea-AI Summary
BioVie to present blinded data on Phase 3 clinical trial of NE3107 for Alzheimer's Disease at CTAD conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.1%
Tags
conferences
News
BioVie Announces Completion of Last Patient Treatment Visit in Phase 3 Trial of NE3107 in Mild to Moderate Alzheimer's Disease
Rhea-AI Summary
BioVie Inc. announces completion of Phase 3 study for NE3107 in Alzheimer's Disease patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.62%
Tags
clinical trial
Stock BIVI logo
BioVie Inc

Nasdaq:BIVI

BIVI Rankings

#5024 Ranked by Market Cap
#3582 Ranked by Stock Gains
N/A Ranked by Dividends

BIVI Stock Data

26.80M
22.51M
43.25%
4.49%
2.69%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States
Carson City

About BIVI

biovie inc. (otc pink: bivi) is developing novel drug therapies for life-threatening complications of chronic liver disease. our initial target is ascites, which can occur in patients with advanced cirrhosis due to hepatitis, nash (non-alcoholic steatohepatitis), or alcoholism. ascites affects about 100,000 americans and carries an estimated 40% mortality rate within two years of being diagnosed. the company’s new drug candidate biv201 is about to enter a phase 2 clinical trial in the us. it’s based on a drug (terlipressin) not yet available in the us, but approved in about 40 countries for treating related complications of liver cirrhosis. the fda has never approved a drug to treat ascites and there is a significant unmet medical need for our novel therapy, which has orphan drug status. biovie has attracted funding from strategic investors including aspire capital, cuong do, the global strategy lead for samsung, and hari kumar, founder of adheron therapeutics which he sold to roche fo